MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

104.20
-3.01
-2.81%
After Hours: 104.20 0 0.00% 16:56 03/27 EDT
OPEN
105.02
PREV CLOSE
107.21
HIGH
106.83
LOW
98.62
VOLUME
719.93K
TURNOVER
--
52 WEEK HIGH
134.51
52 WEEK LOW
65.81
MARKET CAP
11.78B
P/E (TTM)
-12.8062
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALNY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALNY stock price target is 141.45 with a high estimate of 200.00 and a low estimate of 75.00.

EPS

ALNY News

More
  • Big Pharma and Biotech Need to Do More in the Fight Against Covid-19
  • Barrons.com · 1d ago
  • Pfizer's Upjohn Combo With Mylan Is Delayed What That Means For PFE Stock
  • Investor's Business Daily · 2d ago
  • Alnylam establishes Onpattro distribution in Turkey
  • seekingalpha · 4d ago
  • Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in-Class Gene-Silencing RNAi Therapeutic
  • Business Wire · 4d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
More

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.